Subcutaneous her2 antibody formulations

Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatme...

Full description

Saved in:
Bibliographic Details
Main Authors LIN, JASPER, ALAVATTAM, SREEDHARA, GARG, AMIT, KIRSCHBROWN, WHITNEY, WURTH, CHRISTINE, KHAN, TARIK, ENG-WONG, JENNIFER, HEESON, SARAH, BADOVINAC-CRNJEVIC, TANJA
Format Patent
LanguageChinese
English
Published 11.05.2024
Subjects
BABY COMFORTERS
CHEMISTRY
CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICALPURPOSES
DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY
DEVICES FOR RECEIVING SPITTLE
DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGINGPHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL ORADMINISTERING FORMS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
Bibliography:Application Number: TW202110120880